


Express Mail Label No.: EV473991789US

Date of Deposit: September 28, 2005



Atty. Docket No. 21402-042 (CURA 342)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Rastelli *et al.*

SERIAL NUMBER: 10/016,253

EXAMINER: Rawlings, Stephen L.

FILING DATE: December 10, 2001

ART UNIT: 1642

FOR: METHOD OF DETECTING AND TREATING TUBEROUS SCLEROSIS
COMPLEX ASSOCIATED DISORDERS

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Transmitted herewith for filing in the above-referenced patent application are the following documents which were previously filed on August 15, 2005. A copy of these documents are now being transmitted separately to each case listed on Schedule A, so the documents can be more easily matched up with the relevant file.

1. Revocation by Assignee and New Power of Attorney (2 pgs.)
with attached Schedule A (4 pgs.);
2. Return postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any additional fees that may be due to the undersigned's account, Deposit Account No. 50-0311, Ref. No. 21402-042 (CURA 342). A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Naomi S. Biswas, No. 38,384
Attorneys for Applicant
c/o MINTZ LEVIN
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 55111

Dated: September 28, 2005

Express Mail Label No.: EQ 128341435 US

Date of Deposit: August 15, 2005

Attorney Docket No.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ASSIGNEE: CuraGen Corporation
SERIAL NUMBER: See Attached Schedule A
FILING DATE: See Attached Schedule A
FOR: See Attached Schedule A

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REVOCATION BY ASSIGNEE AND NEW POWER OF ATTORNEY

CuraGen Corporation, a company and owner ("Assignee") of the patents and patent applications listed on the attached Schedule A, hereby revokes any and all former powers of attorney and hereby appoints the attorneys and/or agents associated with Customer Number 55111, as Applicants' attorneys with full power of substitution and revocation to take any and all action necessary with regard to the patent application.


Please address all telephone calls to Ivor R. Elrifi at telephone number 617/348-1747.

Please address all correspondence to Customer No. 55111.

EQ128341435US

The undersigned is authorized to act on behalf of the Assignee in the above-referenced patent application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'G. Yahwak', is written over a horizontal line.

George M. Yahwak, Esq.


TITLE: Director of Intellectual Property

REGISTRATION NO. 26, 824

COMPANY: CuraGen Corporation

Date: Monday, August 15, 2005

TRA 2055379v1



Schedule A

U.S. APPLICATIONS

Docket No.	Title	Filing Date	Application No.	Assignment Reel and Frame Nos.
21402-018 CURA 318	Method of Detecting Inflammatory Lung Disorders	May 25, 2001	09/865,812	R# F# Abandoned
21402-018 DIV CURA 318 DIV	Method of Detecting Inflammatory Lung Disorders	July 2, 2003	10/613,105	R# F#
21402-042 CURA 342	Methods of Detecting and Treating Tuberos Sclerosis Complex Associated Disorders	Dec. 10, 2001	10/016,253	R#013294 F#0484
21402-048 CURA 348	Therapeutic Polypeptides, Nucleic Acids Encoding Same, and methods of Use	March 19, 2003	10/391,939	R3 F#
21402-502A CURA 802A	Therapeutic Polypeptides, Nucleic Acids Encoding Same, and Methods of Use	Dec. 2, 2002	10/309,290	R#013968 F#0584
21402-660 CURA 960	Compositions and Methods for Treating T-Cell Mediated Pathological Conditions	January 31, 2005	11/047,207	R# F#
15966-5570M CURA 570M	Compositions and Methods of Use for a Fibroblast Growth Factor	May 9, 2003	10/435,087	R#015013 F#0343

Docket No.	Title	Filing Date	Application No.	Assignment Reel and Page No.
15966-557 IBD CIP3 CURA57IBDCIP3	Methods of Preventing an Treating Inflammatory Bowel Disease	Nov. 3, 2004	10/890,764	R# F#
15966-557A IBDCIP2 CURA 57 A IBD CIP2	Treatment of Inflammatory Bowel Disease Using Growth Factors	Dec. 16, 2002	10/321,962	R# F#
15966-557A IBDCIP CURA 57 A IBDCIP	Treatment of Inflammatory Bowel Disease Using Growth Factors	November 16, 2001	10/011,364	R# F#
15966-557 CON CURA 57 CON	Novel Fibroblast Growth Factor and Nucleic Acids Encoding Same	December 30, 2004	11/027,948	R# F#
15966-557 CIP4 CURA 57CIP4	Novel Fibroblast Grown Factor and Nucleic Acids Encoding Same	Nov. 3, 2004	10/980,659	R# F#
15966-557 CIP3 CURA 57 CIP3	Novel Fibroblast Growth Factor and Nucleic Acids Encoding Same	June 17, 2002	10/174,394	R#013630 F#0882
15966-557 CIP2CON1 CURA 57 CIP2CON1	Antibodies to Fibroblast Growth Factor and Their Methods of Use	Sept. 23, 2004	10/948,588	R# F#

Docket No.	Title	Filing Date	Application No.	Assignment Reel and Frame Nos.
15966-557 CIP1 CURA 57 CIP1	Novel Fibroblast Growth Factor and Nucleic Acids Encoding Same	July 3, 2000	09/609,543	R#011317 F#0748
15966-557A CURA 57A	Treatment of Inflammatory Bowel Disease Using Growth Factors	Nov. 6, 2001	09/992,840	R#015497 F#0582
15966-557 OA CIP CURA 57 OA CIP	Fibroblast Growth Factor 20 and Methods of Use Thereof	Nov. 3, 2004	10/980,458	R# F#
15966-557 OA CURA 57 OA	Novel Fibroblast Growth Factors and Methods of Use Thereof	May 10, 2004	10/842,206	R# F#
15966-557RP CIP1 CURA 57RP CIP1	Prophylactic and Therapeutic Uses of FGF-20 in Radiation Protection	Nov. 3, 2004	10/980,695	R# F#
15966-557 RP CURA 57 RP	Therapeutic Use of G53135-05 (FGF-20) in Radiation Protection	May 10, 2004	10/842,179	R# F#
15966-557 SNP CURA 57 SNP	Compositions and Methods of Use For a Fibroblast Growth Factor	Nov. 4, 2003	10/702,126	R# F#
15966-557 PO CURA 57 PO	Methods For Diagnosing and Treatment of Conditions That Alter Phosphate Transport in Mammals	August 20, 2003	10/644,349	R#014925 F#0846
15966-557 FP CURA 57 FP	Formulations and Methods of Production of FGF-20	Nov. 3, 2004	10/980,370	R# F#

Docket No.	Title	Filing Date	Application No.	Assignment Reel and Frame Nos.
15966-557 AM CURA 57 AM	Method of Preventing and Treating Alimentary Mucositis	Nov. 3, 2004	10/980,459	R# F#
15966-577 CURA 77	Growth Factor Polypeptides and Nucleic Acids Encoding Same	Sept. 12, 2000	09/688,312	R#015523 F#0696
15966-577 CON CURA 77 CON	Growth Factor Polypeptides and Nucleic Acids Encoding Same	April 1, 2005	11/096,308	R# F#
15966-577 A CURA 77 A	Growth Factor Polypeptides and Nucleic Acids Encoding Same	October 5, 2000	09/685,330	R#011534 F#0346 Abandoned
15966-577A CIP CURA 77A CIP	Growth Factor Polypeptides and Nucleic Acids Encoding Same	October 13, 2000	09/688,312	R# F# Abandoned
15966-577A CIP2 CURA 77A CIP2	Growth Factor Polypeptides and Nucleic Acids Encoding Same	November 16, 2000	09/717,332	R# F# Abandoned
15966-577A CIP3 CURA 77A CIP3	Growth Factor Polypeptides and Nucleic Acids Encoding Same	February 2, 2001	09/775,482	R#012218 F#0294 Abandoned